Abstract Number: 1245 • ACR Convergence 2025
Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)
Background/Purpose: Fibromyalgia is a chronic condition marked by widespread pain that can significantly reduce a patient’s quality of life. While low-dose naltrexone (LDN) has emerged…Abstract Number: 0225 • ACR Convergence 2025
Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…Abstract Number: 1244 • ACR Convergence 2025
PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems
Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing…Abstract Number: 0197 • ACR Convergence 2025
Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…Abstract Number: 1242 • ACR Convergence 2025
Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
Background/Purpose: Fibromyalgia (FM) is a multifaceted disorder defined by chronic widespread pain, sleep disruption, fatigue, and cognitive difficulties. Although the predominant theory behind FM pathogenesis…Abstract Number: 1243 • ACR Convergence 2025
Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study
Background/Purpose: Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, cognitive disturbances, and poor sleep. Despite accumulating evidence of immune involvement, a…Abstract Number: 1237 • ACR Convergence 2025
Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
Background/Purpose: Guidelines for fibromyalgia treatment recommend non-pharmacologic treatment, including cognitive behavioral therapy, alongside medications [1-3]. However, patient access to multi-modal treatment is frequently limited due…Abstract Number: 1236 • ACR Convergence 2025
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Background/Purpose: Fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are prototypical nociplastic disorders marked by centralized pain & fatigue, respectively. Nociplastic symptoms — such as…Abstract Number: 1234 • ACR Convergence 2025
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…Abstract Number: 1231 • ACR Convergence 2025
TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Background/Purpose: FDA-approved treatments for fibromyalgia (FM) have historically been limited by intolerable side effects that often lead to poor adherence. TNX-102 SL, a sublingual formulation…Abstract Number: 1228 • ACR Convergence 2025
Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Background/Purpose: Evidence-based behavioral treatments for chronic pain are largely inaccessible, particularly to rural patients. This decentralized randomized controlled trial compared the effectiveness of two digital,…Abstract Number: 1220 • ACR Convergence 2024
Fibromyalgia’s Under-Representation in Rheumatology Literature: A Ten-Year Analysis of Disease-Specific Article Distribution
Background/Purpose: Recent estimates predict that up to 12 million adults in the United States suffer from Fibromyalgia Syndrome (FMS). That is compared to around 1.3…Abstract Number: 0327 • ACR Convergence 2024
Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…Abstract Number: 1221 • ACR Convergence 2024
Efficacy of Immersive Virtual Reality-based Biofeedback on Chronic Pain and Daily Life Impact in Fibromyalgia: A Pilot Randomized Controlled Trial
Background/Purpose: Fibromyalgia (FM) affects 2% of the global population, causing chronic musculoskeletal pain, fatigue, sleep and mood disorders, significantly impacting quality of life. Although many…Abstract Number: 0561 • ACR Convergence 2024
Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort
Background/Purpose: A growing arsenal of biologic/targeted synthetic DMARDs often makes inflammation control an attainable target in axial spondyloarthritis (axSpA). Yet, many patients keep suffering from…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 25
- Next Page »
